Stock Events

Stock Events

Veracyte 

€31.6
86
+€3.51+12.5% Today

Statistics

Day High
32.01
Day Low
31.56
52W High
41.6
52W Low
19.7
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q4 2025
Q1 2026
Next
0.28
0.34
0.39
0.45
Expected EPS
0.35743472099
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 12V.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap11.61B
Guardant Health offers liquid biopsy tests that compete with Veracyte's genomic diagnostics for cancer.
Illumina
ILMN
Mkt Cap20.63B
Illumina provides genomic sequencing technologies and services that are foundational to the development of tests like those offered by Veracyte.
Fulgent Genetics
FLGT
Mkt Cap407.57M
Fulgent Genetics provides comprehensive genetic testing services, competing in the same space as Veracyte.
Bionano Genomics
BNGO
Mkt Cap13.09M
Bionano Genomics offers genomic analysis tools, competing with Veracyte in the genomic diagnostics market.
Pacific Biosciences of California
PACB
Mkt Cap496.78M
Pacific Biosciences offers sequencing technologies that compete with the genomic analysis and diagnostics provided by Veracyte.
Qiagen NV
QGEN
Mkt Cap7.06B
Qiagen provides sample and assay technologies for molecular diagnostics, competing with Veracyte in the diagnostics market.
Myriad Genetics
MYGN
Mkt Cap466.55M
Myriad Genetics offers genetic testing and personalized medicine, directly competing with Veracyte in the genetic diagnostics market.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is involved in CRISPR technology for gene editing, which could compete with Veracyte's genomic diagnostics by offering alternative approaches to understanding and treating diseases.

About

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Marc A. Stapley
Employees
755
Country
United States
ISIN
US92337F1075

Listings

F
DE
12V.F
STU
DE
12V.STU
BOATS
BOATS
VCYT.BOATS
XNAS
US
VCYT

0 Comments

Share your thoughts

FAQ

What is Veracyte stock price today?▼
The current price of 12V.STU is €31.6 EUR — it has increased by +12.5% in the past 24 hours. Watch Veracyte stock price performance more closely on the chart.
What is Veracyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Veracyte stocks are traded under the ticker 12V.STU.
Is Veracyte stock price growing?▼
12V.STU stock has risen by +16.82% compared to the previous week, the month change is a +13.67% rise, over the last year Veracyte has showed a +18.8% increase.
When is the next Veracyte earnings date?▼
Veracyte is going to release the next earnings report on August 11, 2026.
What were Veracyte earnings last quarter?▼
12V.STU earnings for the last quarter are 0.44 EUR per share, whereas the estimation was 0.28 EUR resulting in a +55.89% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Veracyte have?▼
As of May 06, 2026, the company has 755 employees.
In which sector is Veracyte located?▼
Veracyte operates in the Health & Wellness sector.
When did Veracyte complete a stock split?▼
Veracyte has not had any recent stock splits.
Where is Veracyte headquartered?▼
Veracyte is headquartered in South San Francisco, United States.